Literature DB >> 9016760

Effect of concentration on the cytotoxic mechanism of doxorubicin--apoptosis and oxidative DNA damage.

I Müller1, A Jenner, G Bruchelt, D Niethammer, B Halliwell.   

Abstract

Anthracycline derivatives such as doxorubicin are part of many chemotherapeutic regimens and reach peak plasma concentrations of 5 microM. We investigated the cytotoxic mechanisms of various doxorubicin concentrations in MOLT-4 ALL-cells. Concentrations of up to 100 microM doxorubicin achieved similar cytotoxic effects in cultures of MOLT-4 cells, but acted via different mechanisms. Doxorubicin induced apoptosis (maximum effect at 1 microM), which was dependent on RNA synthesis and involved oxidative stress. Concentrations higher than 3 microM did not induce apoptosis, but significantly inhibited RNA synthesis. DNA strand breaks in MOLT-4 cells occurred in the presence of 1 to 5 microM doxorubicin to a similar extent, but showed a dose-dependence at higher concentrations. There was no GC/MS-detectable oxidation of DNA bases in apoptotic cells and only 1 out of 13 DNA base oxidation products, 8-hydroxyguanine, increased significantly in the presence of as much as 100 microM doxorubicin. These results suggest that at pharmacologically relevant concentrations apoptosis and not oxidative DNA damage is the main killing mechanism of doxorubicin against ALL-cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016760     DOI: 10.1006/bbrc.1996.5898

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes.

Authors:  V Omelyanenko; P Kopecková; R K Prakash; C D Ebert; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Parameiosis in Aspergillus nidulans in response to doxorubicin.

Authors:  T C A Becker; M A A De Castro-Prado
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

3.  Inverse-micelle synthesis of doxorubicin-loaded alginate/chitosan nanoparticles and in vitro assessment of breast cancer cytotoxicity.

Authors:  Justin G Rosch; Hayden Winter; Allison N DuRoss; Gaurav Sahay; Conroy Sun
Journal:  Colloid Interface Sci Commun       Date:  2018-12-26

4.  In vivo molecular MRI of cell survival and teratoma formation following embryonic stem cell transplantation into the injured murine myocardium.

Authors:  Jaehoon Chung; Kehkooi Kee; Joëlle K Barral; Rajesh Dash; Hisanori Kosuge; Xi Wang; Irving Weissman; Robert C Robbins; Dwight Nishimura; Thomas Quertermous; Renee A Reijo-Pera; Phillip C Yang
Journal:  Magn Reson Med       Date:  2011-05-20       Impact factor: 4.668

5.  Chronic vascular toxicity of doxorubicin in an organ-cultured artery.

Authors:  T Murata; H Yamawaki; M Hori; K Sato; H Ozaki; H Karaki
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

6.  Chemopreventive potential of beta-Sitosterol in experimental colon cancer model--an in vitro and In vivo study.

Authors:  Albert A Baskar; Savarimuthu Ignacimuthu; Gabriel M Paulraj; Khalid S Al Numair
Journal:  BMC Complement Altern Med       Date:  2010-06-04       Impact factor: 3.659

7.  p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance.

Authors:  Ji Yeon Yang; Seon-Ah Ha; Yun-Sik Yang; Jin Woo Kim
Journal:  BMC Cancer       Date:  2010-07-22       Impact factor: 4.430

8.  Anthracycline-based combined chemotherapy in the mouse model.

Authors:  M Popovic; J Kolarovic; M Mikov; S Trivic; B Kaurinovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Apr-Jun       Impact factor: 2.441

9.  Binding of adriamycin to liposomes as a probe for membrane lateral organization.

Authors:  T Söderlund; A Jutila; P K Kinnunen
Journal:  Biophys J       Date:  1999-02       Impact factor: 4.033

10.  Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging.

Authors:  Yu Cheng; Qing Dai; Ramin A Morshed; Xiaobing Fan; Michelle L Wegscheid; Derek A Wainwright; Yu Han; Lingjiao Zhang; Brenda Auffinger; Alex L Tobias; Esther Rincón; Bart Thaci; Atique U Ahmed; Peter C Warnke; Chuan He; Maciej S Lesniak
Journal:  Small       Date:  2014-08-08       Impact factor: 13.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.